LUMMICAR STUDY 1
The Chinese trial behind zevor-cel's approval for multiple myeloma, showing deep and lasting responses with a fully human BCMA CAR-T.
Overview
Phase 1/2 single-arm study at Chinese centres; the phase 2 report (Experimental Hematology and Oncology 2025) described high overall and complete response rates, deep minimal residual disease negativity and predominantly low-grade cytokine release syndrome. Basis of NMPA approval in February 2024. A parallel North American study (LUMMICAR STUDY 2) was run by CARsgen before it refocused on China.
Pages like this
not linked directly; found by shared links- PersonZonghai Li
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, BCMA, Multiple myeloma and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, CAR-T cell therapy and the tag china.
- TrialFUMANBA-1
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- ProductEquecabtagene autoleucel
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- TrialLEGEND-2
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- ProductInaticabtagene autoleucel
Shares CAR-T cell therapy and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy and the tag china.
- TrialRELIANCE
Shares CAR-T cell therapy and the tag china.